Skinvisible, Inc. (SKVI) stock
SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30
$0.16+0.00 (+0.06%)
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for Skinvisible
Skinvisible has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?